ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
期權訓練營
投資學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
獎項與榮譽
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
艾格里房產
70.07
-0.7100
-1.00%
盤後：
70.07
0.0000
0.00%
19:56 EDT
成交量：
131.89萬
成交額：
9,254.36萬
市值：
87.15億
市盈率：
37.84
高：
70.79
開：
70.62
低：
69.96
收：
70.78
52周最高：
82.08
52周最低：
69.56
股本：
1.24億
流通股本：
1.22億
量比：
0.97
換手率：
1.08%
股息：
3.14
股息率：
4.48%
每股收益(TTM):
1.85
每股收益(LYR):
1.77
淨資產收益率：
3.70%
總資產收益率：
2.40%
市淨率：
1.37
市盈率(LYR):
39.59
資料載入中...
總覽
公司
新聞資訊
公告
科倫博泰生物(06990)：核心產品TROP2 ADC蘆康沙妥珠單抗(sac-TMT) 新增適應症上市申請獲國家藥品監督管理局受理
智通财经网
·
05/08
從AACR看中國創新：ADC與雙抗領跑 授權交易見證含金量
21世纪经济报道
·
04/23
創勝集團醫藥-B(06628)公布其新型LIV1 ADC TST013在前列腺癌及 ER陽性╱HER2陰性乳腺癌PDX模型中顯示出強大的抗腫瘤活性的新數據
智通财经
·
04/23
新一代TROP 2 ADC達卓優在華上市
南方财经网
·
04/22
【灣區早參】香港擬建設首個境外國家製造業創新中心；廣州多部門發布城市更新涉税業務工具書
金吾财讯
·
04/22
中國生物製藥(01177)：禮新醫藥於AACR 2026公布兩款ADC最新研究數據
智通财经
·
04/22
瑪貝蘭妥單抗聯合方案獲批，治療二線及以上多發性骨髓瘤成年患者
新京报
·
04/20
卡位ADC、TCE前沿賽道，邁威生物(02493)港股IPO含金量有幾分？
智通财经
·
04/20
邁威生物（2493.HK）：Nectin-4 ADC領跑，ST2單抗蓄勢，多領域佈局下的價值圖譜
格隆汇
·
04/20
【灣區早參】陳茂波：香港需堅持科技創新，全力發展新興產業；廣州聚焦新興產業和民生領域加強立法
金吾财讯
·
04/20
基石藥業-B(02616)攜CS5007(EGFR/HER3)等三款全新/差異化ADC臨床前研究成果亮相AACR年會
智通财经
·
04/20
勃林格殷格翰與再鼎醫藥宣佈合作開發針對DLL3靶向 T 細胞銜接器和ADC聯合療法，用於治療小細胞肺癌及其他神經內分泌癌
美通社
·
04/15
中國生物製藥(01177)：維特柯妥拜單抗「CLDN18.2 ADC」一線胃及胃食管交界部腺癌III期臨床試驗完成首例患者入組
智通财经
·
04/15
加速全球ADC龍頭價值構建，映恩生物-B(09606)推動「H+A」雙資本平台佈局釋放長投信號
智通财经
·
04/15
以色列與黎巴嫩同意啓動直接談判 旨在達成全面和平協議
投资观察
·
04/15
「明星」抗癌藥中國「七連發」：跨國藥企加速重塑在華商業模式
21世纪经济报道
·
04/14
財報前瞻｜艾格里房產本季度營收預計增17.32%，機構觀點偏多
财报Agent
·
04/14
創新藥又一里程碑式突破！首個國產ADC新藥獲批上市，為腫瘤患者帶來新希望
新浪基金
·
04/10
艾格里房產宣佈上調月度現金股息至每股0.267美元，按月增長1.9%
美股速递
·
04/10
百家中國藥企亮相AACR年會，近400項ADC和雙抗成果將驚豔世界！重視創新藥企估值重塑機遇
新浪基金
·
04/07
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/ADC/news?page=5"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ADC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADC\",,,,,undefined,":{"symbol":"ADC","market":"US","secType":"STK","nameCN":"艾格里房產","latestPrice":70.07,"timestamp":1789502400000,"preClose":70.78,"halted":0,"volume":1318880,"hourTrading":{"tag":"盘后","latestPrice":70.07,"preClose":70.07,"latestTime":"19:56 EDT","volume":27080,"amount":1897514.6507,"timestamp":1789516583999,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.010031082226617801,"floatShares":122178283,"shares":124379300,"eps":1.85165,"marketStatus":"未開盤","change":-0.71,"latestTime":"09-15 16:00:00 EDT","open":70.62,"high":70.79,"low":69.96,"amount":92543554.3152,"amplitude":0.011726,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.85165,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789545600000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":766296000000,"exchange":"NYSE","adjPreClose":70.78,"dividendRate":0.044827,"preHourTrading":{"tag":"盘前","latestPrice":70.72,"preClose":70.78,"latestTime":"07:43 EDT","volume":41,"amount":2918.5798750000004,"timestamp":1789472630472,"change":-0.06,"changeRate":-0.000848,"amplitude":0.018649},"postHourTrading":{"tag":"盘后","latestPrice":70.07,"preClose":70.07,"latestTime":"19:56 EDT","volume":27080,"amount":1897514.6507,"timestamp":1789516583999,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.973589,"impliedVol":0.2358,"impliedVolPercentile":0.64},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADC\",,,,,undefined,":{"symbol":"ADC","floatShares":122178283,"roa":"2.40%","roe":"3.70%","lyrEps":1.77,"volumeRatio":0.973589,"shares":124379300,"dividePrice":3.141,"high":70.79,"amplitude":0.011726,"preClose":70.78,"low":69.96,"week52Low":69.56,"pbRate":"1.37","psRate":"11.18","week52High":82.08,"institutionHeld":0.85,"latestPrice":70.07,"eps":1.85165,"divideRate":0.044827,"volume":1318880,"delay":0,"ttmEps":1.85165,"open":70.62,"prevYearClose":72.03,"prevWeekClose":71.23,"prevMonthClose":72.25,"prevQuarterClose":75.74,"fiveDayClose":72.78,"twentyDayClose":74.54,"sixtyDayClose":73.25,"dividendPayoutRate":1.7363850728368737,"dividendFrequency":"M","dividendGrowthYears":10,"dividendGrowthRate":0.026999999999999986,"fiveYearAvgDividendRate":0.041531731300358074},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ADC\",params:#limit:5,,,undefined,":[{"date":"2026-09-30","symbol":"ADC","amount":0.267,"announcedDate":"2026-09-10","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-30","defaultRemindTime":1790775000000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-14","payableDate":"2026-09-30","currency":"USD","dateTimestamp":1790740800000,"payDate":"2026-10-14"},{"date":"2026-08-31","symbol":"ADC","amount":0.267,"announcedDate":"2026-08-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-31","defaultRemindTime":1788183000000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-15","payableDate":"2026-08-31","currency":"USD","dateTimestamp":1788148800000,"payDate":"2026-09-15"},{"date":"2026-07-31","symbol":"ADC","amount":0.267,"announcedDate":"2026-07-14","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-07-31","defaultRemindTime":1785504600000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-14","payableDate":"2026-07-31","currency":"USD","dateTimestamp":1785470400000,"payDate":"2026-08-14"},{"date":"2026-07-30","symbol":"ADC","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2026/06","expectedEps":1.11,"defaultRemindTime":1785441600000,"name":null,"time":"盤後","dateTimestamp":1785384000000,"actualEps":null},{"date":"2026-06-30","symbol":"ADC","amount":0.267,"announcedDate":"2026-06-08","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-30","defaultRemindTime":1782826200000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-07-15","payableDate":"2026-06-30","currency":"USD","dateTimestamp":1782792000000,"payDate":"2026-07-15"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ADC\",market:\"US\",,,undefined,":[{"executeDate":"2016-09-28","recordDate":"2016-09-30","paymentDate":"2016-10-14","value":0.48,"currency":"USD"},{"executeDate":"2016-12-21","recordDate":"2016-12-23","paymentDate":"2017-01-03","value":0.495,"currency":"USD"},{"executeDate":"2017-03-29","recordDate":"2017-03-31","paymentDate":"2017-04-14","value":0.495,"currency":"USD"},{"executeDate":"2017-06-28","recordDate":"2017-06-30","paymentDate":"2017-07-14","value":0.505,"currency":"USD"},{"executeDate":"2017-09-28","recordDate":"2017-09-29","paymentDate":"2017-10-13","value":0.505,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ADC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2381,"buy":0.381,"hold":0.381,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.381,"analysts":21,"updateTime":1784088000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ADC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ADC","date":"2026-09-14","current":37.841925,"percent":0.318108,"low":31.539495,"twenty":37.632574,"median":41.243214,"eighty":43.576571,"high":50.705944,"avg":40.7419,"sd":3.746062,"marketCap":8846218241},"quantilePoints":[{"date":"2021-09-17","current":50.119952,"twenty":31.977009,"median":39.430911,"eighty":44.835833,"marketCap":4879377818},{"date":"2021-09-24","current":47.775985,"twenty":31.977009,"median":39.430911,"eighty":44.888065,"marketCap":4651183223},{"date":"2021-10-01","current":47.352376,"twenty":31.977009,"median":39.430911,"eighty":44.941549,"marketCap":4609943235},{"date":"2021-10-08","current":47.670083,"twenty":31.977009,"median":39.430911,"eighty":44.9864,"marketCap":4640873226},{"date":"2021-10-15","current":49.02563,"twenty":31.977009,"median":39.430911,"eighty":45.094688,"marketCap":4772841185},{"date":"2021-10-22","current":49.5269,"twenty":31.977009,"median":39.430911,"eighty":45.190701,"marketCap":4821641836},{"date":"2021-10-29","current":50.169373,"twenty":32.013133,"median":39.571166,"eighty":45.28245,"marketCap":4884189150},{"date":"2021-11-05","current":43.773853,"twenty":32.013133,"median":39.651928,"eighty":45.28245,"marketCap":4934976633},{"date":"2021-11-12","current":43.137928,"twenty":32.029424,"median":39.72736,"eighty":45.28245,"marketCap":4863283742},{"date":"2021-11-19","current":43.008274,"twenty":32.198132,"median":39.802558,"eighty":45.28245,"marketCap":4848666745},{"date":"2021-11-26","current":42.662528,"twenty":32.27459,"median":39.842867,"eighty":45.28245,"marketCap":4809688086},{"date":"2021-12-03","current":42.508177,"twenty":32.348817,"median":39.911012,"eighty":45.28245,"marketCap":4792286899},{"date":"2021-12-10","current":42.891493,"twenty":32.447032,"median":39.953188,"eighty":45.28245,"marketCap":4835501148},{"date":"2021-12-17","current":45.380751,"twenty":32.521786,"median":39.996581,"eighty":45.380751,"marketCap":5116135105},{"date":"2021-12-23","current":46.352906,"twenty":32.588031,"median":40.079057,"eighty":45.406143,"marketCap":5225733953},{"date":"2021-12-31","current":48.175698,"twenty":32.64443,"median":40.10618,"eighty":45.47788,"marketCap":5431231792},{"date":"2022-01-07","current":46.703962,"twenty":32.651599,"median":40.164071,"eighty":45.565296,"marketCap":5265311314},{"date":"2022-01-14","current":46.015352,"twenty":32.70478,"median":40.208708,"eighty":45.667046,"marketCap":5187678797},{"date":"2022-01-21","current":43.267663,"twenty":32.731462,"median":40.224323,"eighty":45.667046,"marketCap":4877909831},{"date":"2022-01-28","current":43.821252,"twenty":32.743358,"median":40.249944,"eighty":45.667046,"marketCap":4940320287},{"date":"2022-02-04","current":42.666817,"twenty":32.769192,"median":40.314701,"eighty":45.667046,"marketCap":4810171655},{"date":"2022-02-11","current":42.565551,"twenty":32.769192,"median":40.347561,"eighty":45.667046,"marketCap":4798755108},{"date":"2022-02-18","current":42.943612,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4841376882},{"date":"2022-02-25","current":37.784604,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4620036905},{"date":"2022-03-04","current":38.267307,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4679058463},{"date":"2022-03-11","current":37.29027,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4559593141},{"date":"2022-03-18","current":37.24956,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4554615419},{"date":"2022-03-25","current":38.110019,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4659826391},{"date":"2022-04-01","current":39.298046,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4805089927},{"date":"2022-04-08","current":39.763938,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4862056020},{"date":"2022-04-14","current":40.742313,"twenty":32.769192,"median":40.404479,"eighty":45.667046,"marketCap":4981684815},{"date":"2022-04-22","current":42.01187,"twenty":32.769192,"median":40.455317,"eighty":45.667046,"marketCap":5136917418},{"date":"2022-04-29","current":39.554287,"twenty":32.79826,"median":40.479695,"eighty":45.667046,"marketCap":4836421278},{"date":"2022-05-06","current":39.499614,"twenty":32.904642,"median":40.479695,"eighty":45.667046,"marketCap":5066773466},{"date":"2022-05-13","current":39.967203,"twenty":32.996397,"median":40.479695,"eighty":45.667046,"marketCap":5126753027},{"date":"2022-05-20","current":39.90291,"twenty":33.05702,"median":40.479695,"eighty":45.667046,"marketCap":5118505838},{"date":"2022-05-27","current":40.353768,"twenty":33.088236,"median":40.495181,"eighty":45.667046,"marketCap":5176339242},{"date":"2022-06-03","current":40.599257,"twenty":33.156377,"median":40.53176,"eighty":45.667046,"marketCap":5207829139},{"date":"2022-06-10","current":41.119461,"twenty":33.227354,"median":40.613635,"eighty":45.667046,"marketCap":5274557730},{"date":"2022-06-17","current":40.213488,"twenty":33.270165,"median":40.613635,"eighty":45.667046,"marketCap":5158345016},{"date":"2022-06-24","current":43.32302,"twenty":33.260026,"median":40.659236,"eighty":45.668114,"marketCap":5557217043},{"date":"2022-07-01","current":42.978166,"twenty":33.330747,"median":40.684242,"eighty":45.668114,"marketCap":5512981235},{"date":"2022-07-08","current":42.872956,"twenty":33.466784,"median":40.715658,"eighty":45.668114,"marketCap":5499485565},{"date":"2022-07-15","current":43.708789,"twenty":33.59929,"median":40.742313,"eighty":45.668114,"marketCap":5606701167},{"date":"2022-07-22","current":44.556311,"twenty":33.59929,"median":40.778643,"eighty":45.668114,"marketCap":5715416287},{"date":"2022-07-29","current":46.520226,"twenty":33.675236,"median":40.820493,"eighty":45.678143,"marketCap":5967335462},{"date":"2022-08-05","current":43.100932,"twenty":33.675236,"median":40.862996,"eighty":45.68777,"marketCap":6116022220},{"date":"2022-08-12","current":44.318758,"twenty":33.675236,"median":40.912721,"eighty":45.68777,"marketCap":6288831702},{"date":"2022-08-19","current":44.509569,"twenty":33.675236,"median":40.969109,"eighty":45.68777,"marketCap":6315907842},{"date":"2022-08-26","current":43.241234,"twenty":33.675236,"median":41.010201,"eighty":45.68777,"marketCap":6135931147},{"date":"2022-09-02","current":41.585665,"twenty":33.675236,"median":41.060268,"eighty":45.68777,"marketCap":5901005814},{"date":"2022-09-09","current":41.956063,"twenty":33.675236,"median":41.092655,"eighty":45.68777,"marketCap":5953565380},{"date":"2022-09-16","current":40.805583,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5790312183},{"date":"2022-09-23","current":39.935707,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5666876838},{"date":"2022-09-30","current":37.927001,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5381841428},{"date":"2022-10-07","current":36.428553,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5169211706},{"date":"2022-10-14","current":35.631626,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5056127734},{"date":"2022-10-21","current":36.636203,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5198677248},{"date":"2022-10-28","current":38.359137,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5443161610},{"date":"2022-11-04","current":41.724424,"twenty":33.675236,"median":41.119461,"eighty":45.68777,"marketCap":6035896875},{"date":"2022-11-11","current":42.347632,"twenty":33.675236,"median":41.160749,"eighty":45.68777,"marketCap":6126050848},{"date":"2022-11-18","current":42.756995,"twenty":33.675236,"median":41.197005,"eighty":45.68777,"marketCap":6185269635},{"date":"2022-11-25","current":43.056379,"twenty":33.675236,"median":41.218321,"eighty":45.68777,"marketCap":6228578896},{"date":"2022-12-02","current":43.196907,"twenty":33.675236,"median":41.257018,"eighty":45.68777,"marketCap":6248907733},{"date":"2022-12-09","current":43.795676,"twenty":33.675236,"median":41.35326,"eighty":45.68777,"marketCap":6335526256},{"date":"2022-12-16","current":43.172467,"twenty":33.675236,"median":41.423201,"eighty":45.68777,"marketCap":6245372283},{"date":"2022-12-23","current":43.685698,"twenty":33.675236,"median":41.463369,"eighty":45.68777,"marketCap":6319616732},{"date":"2022-12-30","current":43.337434,"twenty":33.675236,"median":41.483593,"eighty":45.68777,"marketCap":6269236570},{"date":"2023-01-06","current":43.245786,"twenty":34.167053,"median":41.539601,"eighty":45.68777,"marketCap":6255978633},{"date":"2023-01-13","current":45.714181,"twenty":34.992765,"median":41.587683,"eighty":45.704396,"marketCap":6613059075},{"date":"2023-01-20","current":45.402576,"twenty":35.880519,"median":41.605991,"eighty":45.714503,"marketCap":6567982088},{"date":"2023-01-27","current":45.378137,"twenty":36.169649,"median":41.646285,"eighty":45.714503,"marketCap":6564446638},{"date":"2023-02-03","current":45.255939,"twenty":36.592515,"median":41.674422,"eighty":45.714503,"marketCap":6546769389},{"date":"2023-02-10","current":44.406665,"twenty":36.713651,"median":41.711398,"eighty":45.714503,"marketCap":6423912504},{"date":"2023-02-17","current":44.157808,"twenty":36.89773,"median":41.739833,"eighty":45.714503,"marketCap":6731283715},{"date":"2023-02-24","current":42.410386,"twenty":36.963658,"median":41.754028,"eighty":45.714503,"marketCap":6464912060},{"date":"2023-03-03","current":41.690165,"twenty":37.214665,"median":41.783816,"eighty":45.714503,"marketCap":6355123742},{"date":"2023-03-10","current":39.423241,"twenty":37.286636,"median":41.783816,"eighty":45.714503,"marketCap":6009560514},{"date":"2023-03-17","current":40.355986,"twenty":37.342014,"median":41.783816,"eighty":45.714503,"marketCap":6151745384},{"date":"2023-03-24","current":39.606247,"twenty":37.466803,"median":41.783816,"eighty":45.714503,"marketCap":6037457546},{"date":"2023-03-31","current":40.621801,"twenty":37.536428,"median":41.78137,"eighty":45.714342,"marketCap":6192265465},{"date":"2023-04-06","current":39.692254,"twenty":37.577737,"median":41.783816,"eighty":45.714503,"marketCap":6050568092},{"date":"2023-04-14","current":39.289647,"twenty":37.687654,"median":41.784219,"eighty":45.714663,"marketCap":5989195981},{"date":"2023-04-21","current":39.792905,"twenty":37.872566,"median":41.784621,"eighty":45.714824,"marketCap":6065911119},{"date":"2023-04-28","current":40.118543,"twenty":37.943837,"median":41.797292,"eighty":45.714985,"marketCap":6115550327},{"date":"2023-05-05","current":39.964605,"twenty":38.110019,"median":41.797292,"eighty":45.714985,"marketCap":6092084520},{"date":"2023-05-12","current":39.104119,"twenty":38.249787,"median":41.797292,"eighty":45.714985,"marketCap":6176026400},{"date":"2023-05-19","current":38.898029,"twenty":38.342909,"median":41.797292,"eighty":45.714985,"marketCap":6143476946},{"date":"2023-05-26","current":37.796919,"twenty":38.456408,"median":41.797292,"eighty":45.714985,"marketCap":5969569863},{"date":"2023-06-02","current":37.832249,"twenty":38.456408,"median":41.797292,"eighty":45.714985,"marketCap":5975149770},{"date":"2023-06-09","current":38.668386,"twenty":38.476762,"median":41.797292,"eighty":45.714985,"marketCap":6107207554},{"date":"2023-06-16","current":38.786152,"twenty":38.533217,"median":41.797292,"eighty":45.714985,"marketCap":6125807242},{"date":"2023-06-23","current":38.509402,"twenty":38.553397,"median":41.809962,"eighty":45.718688,"marketCap":6082097976},{"date":"2023-06-30","current":38.55062,"twenty":38.5799,"median":41.81327,"eighty":45.72239,"marketCap":6088607866},{"date":"2023-07-07","current":38.662498,"twenty":38.628346,"median":41.81327,"eighty":45.72239,"marketCap":6106277570},{"date":"2023-07-14","current":38.603615,"twenty":38.628346,"median":41.81327,"eighty":45.72239,"marketCap":6096977726},{"date":"2023-07-21","current":39.357316,"twenty":38.659115,"median":41.81327,"eighty":45.72239,"marketCap":6216015729},{"date":"2023-07-28","current":39.404422,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":6223455604},{"date":"2023-08-04","current":38.053978,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":6196443469},{"date":"2023-08-11","current":37.511193,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":6108060089},{"date":"2023-08-18","current":36.166029,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5889023018},{"date":"2023-08-25","current":36.531819,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5948585730},{"date":"2023-09-01","current":36.472821,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5938978841},{"date":"2023-09-08","current":35.75304,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5821774794},{"date":"2023-09-15","current":35.446248,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5771818971},{"date":"2023-09-22","current":33.711695,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5489376431},{"date":"2023-09-29","current":32.567126,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5303002783},{"date":"2023-10-06","current":32.649724,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5316452427},{"date":"2023-10-13","current":31.806046,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5179073913},{"date":"2023-10-20","current":32.41963,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5278985560},{"date":"2023-10-27","current":33.181375,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5472604212},{"date":"2023-11-03","current":35.377246,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5834769220},{"date":"2023-11-10","current":34.598655,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5706356142},{"date":"2023-11-17","current":35.425908,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5842795038},{"date":"2023-11-24","current":35.170433,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5800659496},{"date":"2023-12-01","current":36.015934,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5940108073},{"date":"2023-12-08","current":36.873602,"twenty":38.730653,"median":41.843819,"eighty":45.729795,"marketCap":6081563104},{"date":"2023-12-15","current":37.7556,"twenty":38.730653,"median":41.843819,"eighty":45.729795,"marketCap":6227031044},{"date":"2023-12-22","current":37.968496,"twenty":38.730653,"median":41.843819,"eighty":45.729795,"marketCap":6262143995},{"date":"2023-12-29","current":38.607184,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":6367482847},{"date":"2024-01-05","current":38.296964,"twenty":38.756995,"median":41.871582,"eighty":45.73451,"marketCap":6316318262},{"date":"2024-01-12","current":38.090151,"twenty":38.758791,"median":41.871582,"eighty":45.73451,"marketCap":6282208538},{"date":"2024-01-19","current":36.989174,"twenty":38.764196,"median":41.872103,"eighty":45.735522,"marketCap":6100624420},{"date":"2024-01-26","current":36.295741,"twenty":38.758791,"median":41.871582,"eighty":45.73451,"marketCap":5986256523},{"date":"2024-02-02","current":37.232484,"twenty":38.697827,"median":41.871582,"eighty":45.73451,"marketCap":6140753507},{"date":"2024-02-09","current":35.261674,"twenty":38.661168,"median":41.871582,"eighty":45.73451,"marketCap":5815707904},{"date":"2024-02-16","current":33.847315,"twenty":38.629468,"median":41.871582,"eighty":45.73451,"marketCap":5752655855},{"date":"2024-02-23","current":33.670228,"twenty":38.597685,"median":41.871582,"eighty":45.73451,"marketCap":5722558249},{"date":"2024-03-01","current":32.436519,"twenty":38.556509,"median":41.871061,"eighty":45.733498,"marketCap":5512878257},{"date":"2024-03-08","current":33.758772,"twenty":38.535146,"median":41.871061,"eighty":45.733498,"marketCap":5737607052},{"date":"2024-03-15","current":32.6018,"twenty":38.489062,"median":41.871061,"eighty":45.733498,"marketCap":5540969356},{"date":"2024-03-22","current":33.262927,"twenty":38.456408,"median":41.871061,"eighty":45.733498,"marketCap":5653333754},{"date":"2024-03-28","current":33.457723,"twenty":38.385748,"median":41.784621,"eighty":45.733498,"marketCap":5686441121},{"date":"2024-04-05","current":33.192092,"twenty":38.338315,"median":41.766476,"eighty":45.73451,"marketCap":5641294711},{"date":"2024-04-12","current":33.499043,"twenty":38.271415,"median":41.746116,"eighty":45.73451,"marketCap":5693463896},{"date":"2024-04-19","current":32.99201,"twenty":38.226469,"median":41.73308,"eighty":45.73451,"marketCap":5607289064},{"date":"2024-04-26","current":33.647761,"twenty":38.150217,"median":41.720309,"eighty":45.733498,"marketCap":5827926731},{"date":"2024-05-03","current":33.618779,"twenty":38.090151,"median":41.711398,"eighty":45.733498,"marketCap":5822906984},{"date":"2024-05-10","current":34.482434,"twenty":38.029323,"median":41.69585,"eighty":45.733498,"marketCap":5972495456},{"date":"2024-05-17","current":34.986715,"twenty":37.950247,"median":41.66791,"eighty":45.733498,"marketCap":6059839061},{"date":"2024-05-24","current":34.198413,"twenty":37.871294,"median":41.619337,"eighty":45.733498,"marketCap":5923301932},{"date":"2024-05-31","current":34.928752,"twenty":37.820473,"median":41.602226,"eighty":45.733498,"marketCap":6049799566},{"date":"2024-06-07","current":35.908334,"twenty":37.7418,"median":41.585665,"eighty":45.733498,"marketCap":6219467028},{"date":"2024-06-14","current":35.311311,"twenty":37.642264,"median":41.478607,"eighty":45.73451,"marketCap":6116060232},{"date":"2024-06-21","current":35.485201,"twenty":37.563829,"median":41.447441,"eighty":45.735522,"marketCap":6146178716},{"date":"2024-06-28","current":35.734443,"twenty":37.537078,"median":41.447441,"eighty":45.738558,"marketCap":6189348544},{"date":"2024-07-05","current":35.879352,"twenty":37.482188,"median":41.447441,"eighty":45.738558,"marketCap":6214447281},{"date":"2024-07-12","current":36.957471,"twenty":37.418215,"median":41.439295,"eighty":45.738558,"marketCap":6401181884},{"date":"2024-07-15","current":37.189325,"twenty":37.412399,"median":41.439295,"eighty":45.738558,"marketCap":6441339863},{"date":"2024-08-02","current":37.993919,"twenty":37.339153,"median":41.40142,"eighty":45.707657,"marketCap":7107142493},{"date":"2024-08-09","current":38.417922,"twenty":37.339153,"median":41.351038,"eighty":45.669183,"marketCap":7186456557},{"date":"2024-08-16","current":38.455492,"twenty":37.339153,"median":41.248609,"eighty":45.587895,"marketCap":7193484385},{"date":"2024-08-23","current":38.879496,"twenty":37.339153,"median":41.197005,"eighty":45.51208,"marketCap":7272798449},{"date":"2024-08-30","current":39.104915,"twenty":37.339153,"median":41.152223,"eighty":45.432939,"marketCap":7314965420},{"date":"2024-09-06","current":40.19981,"twenty":37.339153,"median":41.109476,"eighty":45.406991,"marketCap":7519776420},{"date":"2024-09-13","current":40.725789,"twenty":37.339153,"median":41.060268,"eighty":45.379705,"marketCap":7618166018},{"date":"2024-09-20","current":39.786541,"twenty":37.339153,"median":41.020981,"eighty":45.296882,"marketCap":7442470307},{"date":"2024-09-27","current":39.931453,"twenty":37.339153,"median":40.992653,"eighty":45.271719,"marketCap":7469577645},{"date":"2024-10-04","current":40.355457,"twenty":37.339153,"median":40.937316,"eighty":45.211095,"marketCap":7548891709},{"date":"2024-10-11","current":39.3196,"twenty":37.339153,"median":40.894276,"eighty":45.159517,"marketCap":7355124439},{"date":"2024-10-18","current":40.731156,"twenty":37.339153,"median":40.838938,"eighty":45.089028,"marketCap":7619169993},{"date":"2024-10-25","current":42.532506,"twenty":37.339153,"median":40.820493,"eighty":45.046981,"marketCap":8077475775},{"date":"2024-10-31","current":40.816625,"twenty":37.339153,"median":40.816625,"eighty":44.988744,"marketCap":7751607762},{"date":"2024-11-08","current":40.076878,"twenty":37.338438,"median":40.773001,"eighty":44.942004,"marketCap":7611120201},{"date":"2024-11-15","current":41.115788,"twenty":37.338438,"median":40.773001,"eighty":44.942004,"marketCap":7808422584},{"date":"2024-11-22","current":41.948003,"twenty":37.338438,"median":40.773001,"eighty":44.914929,"marketCap":7966471090},{"date":"2024-11-29","current":41.773945,"twenty":37.338438,"median":40.773001,"eighty":44.914324,"marketCap":7933415193},{"date":"2024-12-06","current":40.849261,"twenty":37.338438,"median":40.770318,"eighty":44.892115,"marketCap":7757805742},{"date":"2024-12-13","current":40.055121,"twenty":37.338438,"median":40.736734,"eighty":44.892115,"marketCap":7606988214},{"date":"2024-12-20","current":37.770608,"twenty":37.338438,"median":40.680888,"eighty":44.892115,"marketCap":7173129570},{"date":"2024-12-27","current":38.515795,"twenty":37.338438,"median":40.640959,"eighty":44.892115,"marketCap":7314650128},{"date":"2025-01-03","current":37.933788,"twenty":37.338438,"median":40.614232,"eighty":44.892115,"marketCap":7204119473},{"date":"2025-01-10","current":37.906591,"twenty":37.337724,"median":40.580698,"eighty":44.89414,"marketCap":7198954490},{"date":"2025-01-17","current":39.244663,"twenty":37.333873,"median":40.538993,"eighty":44.89414,"marketCap":7453071695},{"date":"2025-01-24","current":38.87479,"twenty":37.333873,"median":40.501145,"eighty":44.89414,"marketCap":7382827915},{"date":"2025-01-31","current":39.761398,"twenty":37.333873,"median":40.465332,"eighty":44.84311,"marketCap":7551206388},{"date":"2025-02-07","current":39.74508,"twenty":37.333873,"median":40.424995,"eighty":44.718497,"marketCap":7548107398},{"date":"2025-02-14","current":40.634976,"twenty":37.333873,"median":40.403761,"eighty":44.67404,"marketCap":7688015540},{"date":"2025-02-21","current":40.363435,"twenty":37.333873,"median":40.374953,"eighty":44.653159,"marketCap":7636640801},{"date":"2025-02-28","current":41.687197,"twenty":37.333873,"median":40.374953,"eighty":44.559412,"marketCap":7887092651},{"date":"2025-03-07","current":42.394335,"twenty":37.33306,"median":40.37194,"eighty":44.562299,"marketCap":8020881032},{"date":"2025-03-14","current":42.767704,"twenty":37.33306,"median":40.383179,"eighty":44.562299,"marketCap":8091521298},{"date":"2025-03-21","current":43.141073,"twenty":37.417052,"median":40.40791,"eighty":44.562299,"marketCap":8162161563},{"date":"2025-03-28","current":42.993988,"twenty":37.479862,"median":40.452151,"eighty":44.562299,"marketCap":8134333580},{"date":"2025-04-04","current":43.440899,"twenty":37.536428,"median":40.487288,"eighty":44.562299,"marketCap":8218887836},{"date":"2025-04-11","current":41.268572,"twenty":37.537078,"median":40.501145,"eighty":44.559412,"marketCap":7807889929},{"date":"2025-04-17","current":44.145605,"twenty":37.540692,"median":40.519212,"eighty":44.559412,"marketCap":8352216066},{"date":"2025-04-25","current":43.782817,"twenty":37.571542,"median":40.572736,"eighty":44.653759,"marketCap":8377141546},{"date":"2025-05-02","current":45.953462,"twenty":37.571542,"median":40.583839,"eighty":44.677947,"marketCap":8792459672},{"date":"2025-05-09","current":43.031008,"twenty":37.571542,"median":40.598117,"eighty":44.677947,"marketCap":8233294969},{"date":"2025-05-16","current":42.422675,"twenty":37.571542,"median":40.624906,"eighty":44.677947,"marketCap":8116900028},{"date":"2025-05-23","current":42.755537,"twenty":37.571542,"median":40.666871,"eighty":44.677947,"marketCap":8180587826},{"date":"2025-05-30","current":42.698147,"twenty":37.571542,"median":40.666871,"eighty":44.677947,"marketCap":8169607171},{"date":"2025-06-06","current":42.411197,"twenty":37.571542,"median":40.666871,"eighty":44.666838,"marketCap":8114703897},{"date":"2025-06-13","current":42.927706,"twenty":37.571542,"median":40.666871,"eighty":44.666838,"marketCap":8213529790},{"date":"2025-06-20","current":43.220395,"twenty":37.563829,"median":40.663552,"eighty":44.606841,"marketCap":8269531129},{"date":"2025-06-27","current":41.894687,"twenty":37.563829,"median":40.663552,"eighty":44.606841,"marketCap":8015878004},{"date":"2025-07-03","current":41.30357,"twenty":37.563829,"median":40.663552,"eighty":44.606841,"marketCap":7902777259},{"date":"2025-07-11","current":40.735409,"twenty":37.563829,"median":40.663552,"eighty":44.606841,"marketCap":7794068777},{"date":"2025-07-18","current":41.234702,"twenty":37.563829,"median":40.663552,"eighty":44.606841,"marketCap":7889600473},{"date":"2025-07-25","current":42.319373,"twenty":37.604201,"median":40.725789,"eighty":44.606841,"marketCap":8097134849},{"date":"2025-08-01","current":42.372392,"twenty":37.604201,"median":40.742491,"eighty":44.606841,"marketCap":7873129491},{"date":"2025-08-08","current":43.918584,"twenty":37.604201,"median":40.752858,"eighty":44.633348,"marketCap":8160424292},{"date":"2025-08-15","current":42.901923,"twenty":37.604201,"median":40.790693,"eighty":44.633348,"marketCap":7971520467},{"date":"2025-08-22","current":44.019656,"twenty":37.604201,"median":40.820493,"eighty":44.633348,"marketCap":8179204204},{"date":"2025-08-29","current":43.199192,"twenty":37.604201,"median":40.894276,"eighty":44.633348,"marketCap":8026755504},{"date":"2025-09-05","current":42.806797,"twenty":37.595885,"median":40.935905,"eighty":44.639951,"marketCap":7953845256},{"date":"2025-09-12","current":43.841294,"twenty":37.604201,"median":40.969944,"eighty":44.633348,"marketCap":8146063183},{"date":"2025-09-19","current":42.527363,"twenty":37.604201,"median":41.008406,"eighty":44.633348,"marketCap":7901924321},{"date":"2025-09-26","current":41.962551,"twenty":37.639342,"median":41.035693,"eighty":44.633348,"marketCap":7796977752},{"date":"2025-10-03","current":42.027951,"twenty":37.639342,"median":41.102705,"eighty":44.633348,"marketCap":7809129460},{"date":"2025-10-10","current":41.974442,"twenty":37.639342,"median":41.115788,"eighty":44.633348,"marketCap":7799187153},{"date":"2025-10-17","current":44.322871,"twenty":37.639342,"median":41.17126,"eighty":44.633348,"marketCap":8235543942},{"date":"2025-10-24","current":44.544295,"twenty":37.639342,"median":41.220151,"eighty":44.656944,"marketCap":8621592904},{"date":"2025-10-31","current":43.1986,"twenty":37.639342,"median":41.2516,"eighty":44.656944,"marketCap":8361132219},{"date":"2025-11-07","current":42.991114,"twenty":37.639342,"median":41.30357,"eighty":44.656944,"marketCap":8320973082},{"date":"2025-11-14","current":43.690638,"twenty":37.639342,"median":41.35326,"eighty":44.656944,"marketCap":8456366743},{"date":"2025-11-21","current":43.68471,"twenty":37.639342,"median":41.452784,"eighty":44.656944,"marketCap":8455219339},{"date":"2025-11-28","current":44.591721,"twenty":37.639342,"median":41.521652,"eighty":44.656944,"marketCap":8630772135},{"date":"2025-12-05","current":44.093754,"twenty":37.639342,"median":41.583569,"eighty":44.656944,"marketCap":8534390208},{"date":"2025-12-12","current":42.244164,"twenty":37.639342,"median":41.619337,"eighty":44.656944,"marketCap":8176400191},{"date":"2025-12-19","current":42.902191,"twenty":37.639342,"median":41.692355,"eighty":44.656944,"marketCap":8303762024},{"date":"2025-12-26","current":42.919976,"twenty":37.639342,"median":41.746748,"eighty":44.656944,"marketCap":8307204236},{"date":"2026-01-02","current":42.700633,"twenty":37.639342,"median":41.754028,"eighty":44.656944,"marketCap":8264750291},{"date":"2026-01-09","current":41.977396,"twenty":37.639342,"median":41.778924,"eighty":44.654358,"marketCap":8124767015},{"date":"2026-01-16","current":42.688777,"twenty":37.639342,"median":41.778924,"eighty":44.603089,"marketCap":8262455483},{"date":"2026-01-23","current":42.700633,"twenty":37.639342,"median":41.778924,"eighty":44.565186,"marketCap":8264750291},{"date":"2026-01-30","current":42.659136,"twenty":37.639342,"median":41.778924,"eighty":44.544295,"marketCap":8256718464},{"date":"2026-02-06","current":45.131184,"twenty":37.639342,"median":41.778924,"eighty":44.513975,"marketCap":8735185890},{"date":"2026-02-13","current":44.908403,"twenty":37.639342,"median":41.778924,"eighty":44.506847,"marketCap":9176987197},{"date":"2026-02-20","current":45.230936,"twenty":37.639342,"median":41.778924,"eighty":44.513975,"marketCap":9242896611},{"date":"2026-02-27","current":46.784962,"twenty":37.639342,"median":41.778924,"eighty":44.52786,"marketCap":9560460154},{"date":"2026-03-06","current":47.517993,"twenty":37.639342,"median":41.778924,"eighty":44.544295,"marketCap":9710254277},{"date":"2026-03-13","current":46.714591,"twenty":37.639342,"median":41.778924,"eighty":44.544295,"marketCap":9546079918},{"date":"2026-03-20","current":46.13403,"twenty":37.639342,"median":41.778924,"eighty":44.544295,"marketCap":9427442972},{"date":"2026-03-27","current":43.629997,"twenty":37.639342,"median":41.778924,"eighty":44.513975,"marketCap":8915746245},{"date":"2026-04-02","current":44.474448,"twenty":37.639342,"median":41.778924,"eighty":44.463484,"marketCap":9088309076},{"date":"2026-04-10","current":45.752298,"twenty":37.639342,"median":41.778924,"eighty":44.447073,"marketCap":9349436265},{"date":"2026-04-17","current":46.315619,"twenty":37.639342,"median":41.778924,"eighty":44.447073,"marketCap":9464550524},{"date":"2026-04-24","current":42.221567,"twenty":37.639342,"median":41.778924,"eighty":44.388105,"marketCap":9263580602},{"date":"2026-05-01","current":42.145034,"twenty":37.639342,"median":41.773945,"eighty":44.310918,"marketCap":9246788997},{"date":"2026-05-08","current":41.718719,"twenty":37.639342,"median":41.749425,"eighty":44.205061,"marketCap":9153253847},{"date":"2026-05-15","current":41.144834,"twenty":37.639342,"median":41.735116,"eighty":44.170042,"marketCap":9027341145},{"date":"2026-05-22","current":41.363457,"twenty":37.639342,"median":41.708673,"eighty":44.159332,"marketCap":9075307889},{"date":"2026-05-29","current":40.745847,"twenty":37.635958,"median":41.645687,"eighty":44.142784,"marketCap":8939801838},{"date":"2026-06-05","current":39.477834,"twenty":37.639342,"median":41.613421,"eighty":44.076208,"marketCap":8661594725},{"date":"2026-06-12","current":40.871555,"twenty":37.639342,"median":41.561825,"eighty":44.020119,"marketCap":8967382716},{"date":"2026-06-18","current":40.341395,"twenty":37.639342,"median":41.522683,"eighty":43.960147,"marketCap":8851063362},{"date":"2026-06-26","current":41.527424,"twenty":37.635958,"median":41.458055,"eighty":43.866662,"marketCap":9111282946},{"date":"2026-07-02","current":41.691391,"twenty":37.635958,"median":41.455214,"eighty":43.838916,"marketCap":9147258004},{"date":"2026-07-10","current":42.549486,"twenty":37.635958,"median":41.455214,"eighty":43.812381,"marketCap":9335527473},{"date":"2026-07-17","current":44.134502,"twenty":37.635958,"median":41.455214,"eighty":43.800235,"marketCap":9683286364},{"date":"2026-07-24","current":43.620739,"twenty":37.635958,"median":41.455214,"eighty":43.790532,"marketCap":9570564516},{"date":"2026-07-31","current":43.306779,"twenty":37.632574,"median":41.452784,"eighty":43.772108,"marketCap":9737919027},{"date":"2026-08-07","current":42.169016,"twenty":37.632574,"median":41.452784,"eighty":43.730794,"marketCap":9482082868},{"date":"2026-08-14","current":41.48415,"twenty":37.632574,"median":41.412647,"eighty":43.686617,"marketCap":9328084404},{"date":"2026-08-21","current":41.119624,"twenty":37.632574,"median":41.35326,"eighty":43.679447,"marketCap":9246117479},{"date":"2026-08-28","current":40.429234,"twenty":37.632574,"median":41.30357,"eighty":43.643751,"marketCap":9090877092},{"date":"2026-09-04","current":40.169647,"twenty":37.632574,"median":41.279794,"eighty":43.619299,"marketCap":9032506706},{"date":"2026-09-11","current":39.48478,"twenty":37.632574,"median":41.2516,"eighty":43.588862,"marketCap":8878508241},{"date":"2026-09-14","current":39.341179,"twenty":37.632574,"median":41.243214,"eighty":43.576571,"marketCap":8846218241}],"updateTime":1789544328995},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ADC\",pageSize:20,pageCount:5,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2633432300","title":"科倫博泰生物(06990)：核心產品TROP2 ADC蘆康沙妥珠單抗(sac-TMT) 新增適應症上市申請獲國家藥品監督管理局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2633432300","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633432300?lang=zh_tw&edition=fundamental","pubTime":"2026-05-08 18:16","pubTimestamp":1778235396,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物 发布公告，近日，本公司靶向人滋养细胞表面抗原2 的抗体偶联药物芦康沙妥珠单抗 (佳泰莱)的一项新增适应症上市申请(该申请)已获中国国家药品监督管理局药品审评中心受理。本次受理是基于OptiTROP-Lung05注册3 期研究的积极结果，该申请是芦康沙妥珠单抗获NMPA受理的第五项适应症上市申请。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439642.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["IPOS","BK4231","06990","ADC","LU0196878994.USD","BK1161","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629001368","title":"從AACR看中國創新：ADC與雙抗領跑 授權交易見證含金量","url":"https://stock-news.laohu8.com/highlight/detail?id=2629001368","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629001368?lang=zh_tw&edition=fundamental","pubTime":"2026-04-23 13:00","pubTimestamp":1776920400,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛1907年的华盛顿，11位医生与科学家随手组建的“小圈子”，谁也没想到会演变成今天全球癌症研究领域最负盛名的盛会——美国癌症研究协会（AACR）。一百多年后的今天，AACR年会早已不只是一场学术会议，更是全球肿瘤研发的“晴雨表”和“风向标”。对中国生物医药产业而言，AACR也成为观察创新活力与国际化进程的最佳窗口。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604233715799065.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604233715799065.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ADC","BK4231","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629079406","title":"創勝集團醫藥-B(06628)公布其新型LIV1 ADC TST013在前列腺癌及 ER陽性╱HER2陰性乳腺癌PDX模型中顯示出強大的抗腫瘤活性的新數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2629079406","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629079406?lang=zh_tw&edition=fundamental","pubTime":"2026-04-23 07:00","pubTimestamp":1776898849,"startTime":"0","endTime":"0","summary":"智通财经APP讯，创胜集团医药-B 公布，于2026年AACR年会上发表强调其自主研发的LIV1抗体偶联药物的临床前数据。对于LIV1表达的前列腺癌PDX模型，ADC-2在给药两剂后显示出有限的肿瘤生长抑制。总体而言，该等数据证明创胜医药的LIV1 ADC-2及ADC-3项目在ER阳性╱Her2 阴性乳腺癌以及前列腺癌的PDX模型中作为单药疗法显示出强大的抗肿瘤活性。该等结果支持进一步研究创胜医药的LIV1 ADC在LIV1阳性实体瘤中的应用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432372.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","06628","BK4080","BK1161","BK1515","PDX","ADC","159938","09939","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629961098","title":"新一代TROP 2 ADC達卓優在華上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2629961098","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629961098?lang=zh_tw&edition=fundamental","pubTime":"2026-04-22 10:13","pubTimestamp":1776823980,"startTime":"0","endTime":"0","summary":"南方财经4月22日电，阿斯利康与第一三共合作开发并引入中国的第二款ADC药物达卓优?（英文商品名:Datroway?，通用名：注射用德达博妥单抗）在中国正式上市，首批到货将陆续在全国各地医院和药房落地启用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604223713715630.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604223713715630.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IPOS","ADC","BK4080","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629062152","title":"【灣區早參】香港擬建設首個境外國家製造業創新中心；廣州多部門發布城市更新涉税業務工具書","url":"https://stock-news.laohu8.com/highlight/detail?id=2629062152","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629062152?lang=zh_tw&edition=fundamental","pubTime":"2026-04-22 08:47","pubTimestamp":1776818855,"startTime":"0","endTime":"0","summary":"一、市场要闻1、香港拟建设首个境外国家制造业创新中心香港特区政府创科及工业局局长孙东21日在立法会工商及创科事务委员会会议上表示，在香港设立国家制造业创新中心既属必要，也具有战略重要性。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/ZTRlMTU1ZDUyYWE0NDQzMjc2MzgzOTI4MA==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZTRlMTU1ZDUyYWE0NDQzMjc2MzgzOTI4MA==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1979603","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06682","LU0314109678.HKD","00551","ADC","BK1190","BK1109","HK0000165453.HKD","BK1175","LU1023057109.AUD","BK1506","BK1168","01177","BK1614","LU0359201612.USD","SG9999011746.SGD","MUCmain","MCNHmain","LU0348766576.USD","BK1515","IE00BYTNYN87.SGD","01208","TME","BK1613","LU0359202008.SGD","BK1171","LU2039709279.SGD","BK1521","LU0348783233.USD","00522","LU1282649141.HKD","01333","BK4526","CYB","01698","LU0348767384.USD","LU0456842615.SGD","LU0348825331.USD","IE00B12V2V27.USD","LU0509642566.USD","BK4552","LU0227179875.USD","BK4535","IND","UCmain","LU1282649810.SGD","IE00BZ08YT58.USD","BK4565","CNHmain","00762","LU0348784397.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629906669","title":"中國生物製藥(01177)：禮新醫藥於AACR 2026公布兩款ADC最新研究數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2629906669","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629906669?lang=zh_tw&edition=fundamental","pubTime":"2026-04-22 06:16","pubTimestamp":1776809789,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 公布，该集团全资附属公司礼新医药科技(上海)有限公司自主研发的两款新一代抗体偶联药物 LM-364 “Nectin-4TME ADC”及LM-338 “STn ADC”，于2026年美国癌症研究协会年会公布最新研究数据。LM-364是礼新医药依托自主开发的肿瘤微环境平台开发的新一代Nectin-4TME ADC。目前，LM-364已向美国食品药品监督管理局递交新药临床试验申请，计划于2026年启动首次人体临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431634.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01177","ADC","BK1191","BK1515","HK0000165453.HKD","BK1161","IE00BZ08YR35.GBP","BK1521","159938","IE00BZ08YT58.USD","09939","BK4231","BK1589","IE00BZ08YS42.EUR","BK4080","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628742381","title":"瑪貝蘭妥單抗聯合方案獲批，治療二線及以上多發性骨髓瘤成年患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2628742381","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628742381?lang=zh_tw&edition=fundamental","pubTime":"2026-04-20 18:35","pubTimestamp":1776681300,"startTime":"0","endTime":"0","summary":"4月20日，葛兰素史克宣布，国家药品监督管理局已批准注射用玛贝兰妥单抗（商品名：倍乐锐）与硼替佐米和地塞米松的联合治疗方案，用于既往接受过至少一线治疗的多发性骨髓瘤成年患者。该联合治疗方案的上市申请已被纳入优先审评审批程序，并被纳入突破性治疗药物程序。多发性骨髓瘤是全球第三大常见的血液癌症，通常被认为是可治但不可治愈的疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604203710832324.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604203710832324.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4231","ADC","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628790385","title":"卡位ADC、TCE前沿賽道，邁威生物(02493)港股IPO含金量有幾分？","url":"https://stock-news.laohu8.com/highlight/detail?id=2628790385","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628790385?lang=zh_tw&edition=fundamental","pubTime":"2026-04-20 09:40","pubTimestamp":1776649207,"startTime":"0","endTime":"0","summary":"2026年4月20日，迈威生物正式启动招股程序，中信证券与海通国际担任联席保荐人。在这一波创新药出海浪潮中，手握全球领先管线的迈威生物无疑将受到市场密切关注。通过ADC与TCE双平台驱动，叠加多元化的创新管线布局，迈威生物正在肿瘤治疗领域构建起差异化的强大竞争壁垒。从业绩来看，迈威生物已交出了一份颇具说服力的答卷：2024-","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430463.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688062","02493","VXUS","BK4080","SPCX","IPOS","BK4231","BK4588","BK4585","BK0239","ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628292792","title":"邁威生物（2493.HK）：Nectin-4 ADC領跑，ST2單抗蓄勢，多領域佈局下的價值圖譜","url":"https://stock-news.laohu8.com/highlight/detail?id=2628292792","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628292792?lang=zh_tw&edition=fundamental","pubTime":"2026-04-20 09:03","pubTimestamp":1776646985,"startTime":"0","endTime":"0","summary":"当A+H双平台为它打开新的资本窗口，当生物医药成为国家支柱产业的大势已经明朗，迈威生物已从一家biotech成长为能自己造血、自己生产、自己卖药的全产业链biopharma，未来值得期待。","market":"hk","thumbnail":"https://img2.gelonghui.com/d273d-800407fd-2249-448f-b352-5198e098082d.jpg?guru_height=855&guru_width=1280&guru_size=118253","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/d273d-800407fd-2249-448f-b352-5198e098082d.jpg?guru_height=855&guru_width=1280&guru_size=118253"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4463975","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["ADC","688062","BK0239","BK4231","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628792140","title":"【灣區早參】陳茂波：香港需堅持科技創新，全力發展新興產業；廣州聚焦新興產業和民生領域加強立法","url":"https://stock-news.laohu8.com/highlight/detail?id=2628792140","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628792140?lang=zh_tw&edition=fundamental","pubTime":"2026-04-20 08:50","pubTimestamp":1776646227,"startTime":"0","endTime":"0","summary":"3、广州聚焦新兴产业和民生领域加强立法广东省广州市人大常委会日前召开立法工作会议，确定今年立法工作计划共安排项目38件，其中新兴领域12件、民生领域15件、城乡建设管理领域9件、文化领域2件。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/ZTRlMTU1ZDUyYWE0NDQzMjc2MzgzOTI4MA==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZTRlMTU1ZDUyYWE0NDQzMjc2MzgzOTI4MA==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1979324","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823413660.USD","IE00BHRH8D16.HKD","IE00BZ08YS42.EUR","BK1589","02039","LU0823413587.USD","BK1135","SG9999001069.SGD","IE00BG0RBZ43.SGD","IE00BHRH8C09.USD","BK1583","BK4080","03323","00788","ADC","BK1616","SG9999001093.SGD","BK1594","BK1521","BK1563","BK1133","BK1503","BK1191","BK4231","IE00BZ08YT58.USD","01177","BK1183","02589","BK1506","BK1587","BK1507","HK0000165453.HKD","BK1529","BK1515","IND","IE00BZ08YR35.GBP","BK1233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628794281","title":"基石藥業-B(02616)攜CS5007(EGFR/HER3)等三款全新/差異化ADC臨床前研究成果亮相AACR年會","url":"https://stock-news.laohu8.com/highlight/detail?id=2628794281","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628794281?lang=zh_tw&edition=fundamental","pubTime":"2026-04-20 08:04","pubTimestamp":1776643475,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 公布，公司在2026年4月17日至22日召开的美国癌症研究协会年会上展出包括CS5007、CS5006及CS5008在内三项自主研发管线的临床前最新研究成果。CS5007是一种双特异性ADC,由抗EGFR/HER3人源IgG1抗体、基石药业专有的亲水性CSL20连接子，以及临床验证的拓扑异构酶I抑制剂Exatecan组成。此外，CS5008抗体产量高、ADC稳定性强、成药性良好。基石药业计划于2026年下半年正式启动CS5008的IND申请工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430419.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4231","ADC","BK4080","02616","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627230348","title":"勃林格殷格翰與再鼎醫藥宣佈合作開發針對DLL3靶向 T 細胞銜接器和ADC聯合療法，用於治療小細胞肺癌及其他神經內分泌癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2627230348","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627230348?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 21:15","pubTimestamp":1776258900,"startTime":"0","endTime":"0","summary":"勃林格殷格翰与再鼎医药启动临床合作，评估双DLL3靶向药物联合疗法在小细胞肺癌及其他神经内分泌癌中的效果。\" Obrixtamig是勃林格殷格翰研发的一款DLL3/CD3双特异性T细胞衔接器，旨在引导人体自身免疫细胞攻击表达DLL3的癌细胞，而DLL3表达是小细胞肺癌及某些神经内分泌癌的标志性特征。Zoci用于小细胞肺癌治疗已获得FDA孤儿药资格及快速通道资格认定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/4935026_ZH35026_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4935026_ZH35026_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4139","BK1574","BK4548","BK4080","09688","BK4526","BK4588","BK1588","BK1161","ADC","BK4531","BK4585","LU2488822045.USD","ZLAB","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627407539","title":"中國生物製藥(01177)：維特柯妥拜單抗「CLDN18.2 ADC」一線胃及胃食管交界部腺癌III期臨床試驗完成首例患者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2627407539","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627407539?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 17:02","pubTimestamp":1776243779,"startTime":"0","endTime":"0","summary":"本研究为LM-302开展的第二项Ⅲ期临床试验，也是全球首个CLDN18.2 ADC药物采用无化疗方案用于胃癌一线治疗的Ⅲ期临床试验。这种“ADC+免疫”联合策略有望为CLDN18.2阳性胃癌患者带来更深度的肿瘤缓解。除本次启动的LM-302联合疗法用于一线治疗CLDN18.2阳性GC/GEJ的III期临床外，LM-302单药用于三线及以上CLDN18.2阳性GC/GEJ的III期临床研究已完成全部受试者入组。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428818.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ADC","BK1191","01177","BK1589","BK4134","BK1521","BK4231","HK0000165453.HKD","BK4080","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","III","BK1515","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627478451","title":"加速全球ADC龍頭價值構建，映恩生物-B(09606)推動「H+A」雙資本平台佈局釋放長投信號","url":"https://stock-news.laohu8.com/highlight/detail?id=2627478451","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627478451?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 08:00","pubTimestamp":1776211200,"startTime":"0","endTime":"0","summary":"4月13日晚，ADC龙头企业映恩生物-B发布公告宣布：董事会批准了发行人民币股份并在科创板上市的计划。对于映恩生物而言，自2025年6月成功实现港股上市后，此次拟申报科创板上市意味着公司正积极锚向“H+A”双资本平台布局，以进一步拓宽企业融资渠道、支持在研管线的临床推进及技术平台建设。作为全球ADC药物创新研发的前沿领导者之一，映恩生物的技术价值也获得了国际业界的高度认可。目前，双方联合用药的临床进展全球领先。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428586.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09606","HK0000500386.USD","LU2543165471.USD","BK4231","HK0000252152.HKD","HK0000252160.HKD","BK4080","BK1161","ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193502109","title":"以色列與黎巴嫩同意啓動直接談判 旨在達成全面和平協議","url":"https://stock-news.laohu8.com/highlight/detail?id=1193502109","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193502109?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 03:26","pubTimestamp":1776194798,"startTime":"0","endTime":"0","summary":"以色列与黎巴嫩宣布，在双方官员举行罕见的面对面会谈后，两国已同意启动直接谈判，以达成全面和平协议。声明强调：\"美方希望此次谈判能超越2024年协议框架，推动达成全面和平协定。以色列驻美大使耶希尔·莱特会后表示，黎巴嫩与以色列立场一致。黎巴嫩官员此前曾提出，全面停火是该国参与谈判的先决条件，但以色列方面始终拒绝作出承诺。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","BK4080","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627494406","title":"「明星」抗癌藥中國「七連發」：跨國藥企加速重塑在華商業模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2627494406","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627494406?lang=zh_tw&edition=fundamental","pubTime":"2026-04-14 13:17","pubTimestamp":1776143820,"startTime":"0","endTime":"0","summary":"近日，由阿斯利康与第一三共共同开发与商业化的德曲妥珠单抗在中国取得新突破：其序贯THP疗法用于HER2阳性早期乳腺癌新辅助治疗的适应症实现“全球首批”，中国患者成为全球最早受益于这一创新疗法的群体。这并非德曲妥珠单抗在中国的首次亮相。自2023年首次获批以来，这款被称为“大魔王”的抗体偶联药物（ADC）在中国接连拿下七项适应症，覆盖乳腺癌、肺癌、胃癌等多个领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604143704221860.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604143704221860.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ADC","06978","BK4231","BK1161","BK1574","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143072653","title":"財報前瞻｜艾格里房產本季度營收預計增17.32%，機構觀點偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1143072653","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143072653?lang=zh_tw&edition=fundamental","pubTime":"2026-04-14 08:52","pubTimestamp":1776127951,"startTime":"0","endTime":"0","summary":"艾格里房产将于2026年04月21日发布最新季度财报，市场关注营收与调整后每股收益的同比增长以及分红持续性。当前公开预期未提供本季度毛利率与净利润或净利率的具体数值。艾格里房产上一季度营收1.90亿美元，同比增长18.51%；毛利率87.40%；归属于母公司股东的净利润为5,603.70万美元，环比增长7.52%；净利率29.42%；调整后每股收益0.47美元，同比增长14.63%。本季度营收一致预期为1.92亿美元、同比增长17.32%，显示租金规模与资产投放节奏仍处在上行区间。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜艾格里房产本季度营收预计增17.32%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626164049","title":"創新藥又一里程碑式突破！首個國產ADC新藥獲批上市，為腫瘤患者帶來新希望","url":"https://stock-news.laohu8.com/highlight/detail?id=2626164049","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626164049?lang=zh_tw&edition=fundamental","pubTime":"2026-04-10 15:07","pubTimestamp":1775804820,"startTime":"0","endTime":"0","summary":"4月9日，映恩生物研发的帕康曲妥珠单抗获得国家药监局批准上市，这是首个获批的国产ADC新药，靶点为HER2，适用于肿瘤治疗。 帕康曲妥珠单抗作为国产ADC药物获批上市，标志着中国在抗体偶联药物领域的创新实力进一步提升。ADC药物结合了靶向治疗与细胞毒杀伤的双重优势，已成为全球肿瘤治疗的重要方向。作为首个获批的国产ADC新药，该药物的上市标志着国内ADC领域的重要突破，有望为HER2阳性乳腺癌患者提供新的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/2026-04-10/doc-inhtzamx5126802.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","BK1574","000876","BK4231","BK4080","BK0183","BK0187","BK0012","IPOS","BK0196","ADC","159992","06978","BK0238","BK1161","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159214626","title":"艾格里房產宣佈上調月度現金股息至每股0.267美元，按月增長1.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1159214626","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159214626?lang=zh_tw&edition=fundamental","pubTime":"2026-04-10 04:06","pubTimestamp":1775765173,"startTime":"0","endTime":"0","summary":"艾格里房产（Agree Realty Corp）最新宣布，将普通股月度现金股息提升至每股0.267美元，较上月增长1.9%。此次调升体现了公司稳健的现金流状况与持续回报股东的承诺。作为以净租赁零售物业为核心业务的房地产投资信托基金，艾格里房产通过定期股息调整，进一步强化其长期价值主张。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","BK4080","ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625805619","title":"百家中國藥企亮相AACR年會，近400項ADC和雙抗成果將驚豔世界！重視創新藥企估值重塑機遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2625805619","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625805619?lang=zh_tw&edition=fundamental","pubTime":"2026-04-07 15:04","pubTimestamp":1775545440,"startTime":"0","endTime":"0","summary":"2026年4月17日至22日，美国圣地亚哥召开的AACR年会将迎来超过100家中国药企的参与，这些企业将共同展示近400项ADC和双特异性抗体等前沿创新研究成果。 4月17日至22日，美国癌症研究协会年会将吸引全球肿瘤学界的目光，而中国创新药企的集体亮相尤为引人注目。2025年已有126家中国药企亮相AACR会议，带来近300项新药研究，今年进一步扩大规模。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/2026-04-07/doc-inhtseyy3559037.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","06978","BK4231","BK4080","BK1161","ADC","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":5,"totalSize":109,"code":"91000000","status":"200"}]}}